Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats

Neuropharmacology. 2005 Jun;48(8):1147-53. doi: 10.1016/j.neuropharm.2005.02.013. Epub 2005 Apr 21.

Abstract

The fatty-acid ethanolamide, oleoylethanolamide (OEA), is a naturally occurring lipid that regulates feeding and body weight [Rodriguez de Fonseca, F., Navarro, M., Gomez, R., Escuredo, L., Nava, F., Fu, J., Murillo-Rodriguez, E., Giuffrida, A., LoVerme, J., Gaetani, S., Kathuria, S., Gall, C., Piomelli, D., 2001. An anorexic lipid mediator regulated by feeding. Nature 414, 209-212], and serves as an endogenous agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) [Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodriguez De Fonseca, F., Rosengarth., A., Luecke, H., Di Giacomo, B., Tarzia, G., Piomelli, D., 2003. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425, 90-93], a ligand-activated transcription factor that regulates several aspects of lipid metabolism [. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688]). OEA reduces food intake in wild-type mice, but not in mice deficient in PPAR-alpha (PPAR-alpha(-/-)), an effect that is also observed with the PPAR-alpha agonists Wy-14643 and GW7647 [Brown, P.J., Chapman, J.M., Oplinger, J.A., Stuart, L.W., Willson, T.M. and Wu, Z., 2000. Chemical compounds as selective activators of PPAR-alpha. PCT Int. Appl., 32; . The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527-550]. By contrast, specific agonists of PPAR-delta/beta (GW501516) or PPAR-gamma (ciglitazone) have no such effect. In obese Zucker rats, which lack functional leptin receptors, OEA reduces food intake and lowers body-weight gain along with plasma lipid levels. Similar effects are seen in diet-induced obese rats and mice. In the present study, we report that subchronic OEA treatment (5mgkg(-1), intraperitoneally, i.p., once daily for two weeks) in Zucker rats initiates transcription of PPAR-alpha and other PPAR-alpha target genes, including fatty-acid translocase (FAT/CD36), liver fatty-acid binding protein (L-FABP), and uncoupling protein-2 (UCP-2). Moreover, OEA decreases neutral lipid content in hepatocytes, as assessed by Oil red O staining, as well as serum cholesterol and triglyceride levels. The results suggest that OEA regulates lipid metabolism and that this effect may contribute to its anti-obesity properties.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Body Weight / drug effects*
  • Butyrates / pharmacology
  • CD36 Antigens / genetics
  • Cholesterol / blood
  • Coenzyme A Ligases / genetics
  • Eating / drug effects*
  • Endocannabinoids
  • Fatty Acid-Binding Proteins / genetics
  • Hepatocytes / metabolism
  • Hyperlipidemias / drug therapy*
  • Ion Channels / genetics
  • Liver / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mitochondrial Proteins / genetics
  • Obesity / drug therapy*
  • Oleic Acids / administration & dosage
  • Oleic Acids / pharmacology*
  • PPAR alpha / agonists*
  • PPAR alpha / genetics
  • Phenylurea Compounds / pharmacology
  • Pyrimidines / pharmacology
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Inbred WF
  • Rats, Zucker
  • Thiazoles / pharmacology
  • Thiazolidinediones / pharmacology
  • Triglycerides / blood
  • Uncoupling Protein 2

Substances

  • Butyrates
  • CD36 Antigens
  • Endocannabinoids
  • Fabp1 protein, rat
  • Fatty Acid-Binding Proteins
  • GW 501516
  • GW 7647
  • Ion Channels
  • Mitochondrial Proteins
  • Oleic Acids
  • PPAR alpha
  • Phenylurea Compounds
  • Pyrimidines
  • RNA, Messenger
  • Thiazoles
  • Thiazolidinediones
  • Triglycerides
  • Ucp2 protein, mouse
  • Ucp2 protein, rat
  • Uncoupling Protein 2
  • oleoylethanolamide
  • pirinixic acid
  • Cholesterol
  • Coenzyme A Ligases
  • ciglitazone